Defer no more: advances in the treatment and prevention of chronic hepatitis C virus infection in children.

ABSTRACT:

Purpose of review

Direct-acting antiviral (DAA) regimens targeting hepatitis C virus (HCV) are now approved for young children. This review examines recent DAA experience in children, current treatment recommendations and challenges, and potential treatment-as-prevention strategies.

Recent findings

In 2021, the US FDA extended approval of two pan-genotypic DAA regimens, glecaprevir/pibrentasvir and sofosbuvir/velpatasvir, to children as young as age 3 years based on high success rates and reassuring safety profiles in registry trials. Similar performance has been replicated with real-world DAA use in thousands of adolescents and in limited reports of children with high-risk conditions, including cirrhosis, cancer, thalassemia and HIV-coinfection. Treatment without delay is n

SUBMITTER: Honegger JR 

PROVIDER: S-EPMC9474609 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature